Search IPOs
QLINE · NSE · Healthcare
Q-Line Biotech IPO listed on 29 May 2026 on NSE at ₹452.00, a gain of 23.21% over the issue price of ₹349.00. The IPO was subscribed 102.49x overall.
Q-Line Biotech IPO tentative timeline covering IPO opening, closing, basis of allotment, refunds, demat credit, and listing dates.
| Event | Date |
|---|---|
| IPO Open Date | 21 May 2026 |
| IPO Close Date | 25 May 2026 |
| Basis of Allotment | 26 May 2026 |
| Initiation of Refunds | 27 May 2026 |
| Credit of Shares to Demat | 27 May 2026 |
| Listing Date | 29 May 2026 |
Listing day gain
+23.21%
Listed at ₹452 (issue ₹349)
Issue
₹349
Listing
₹452
Current
₹474.6
+35.99% vs issue
Day range
₹431 – ₹474.6
Issue Size
6,253,200 shares
(aggregating up to ₹214.00 Cr)
Issue Price
₹326 – ₹349
Face Value
₹10/share
Market Lot
400 shares
Retail Min Investment
₹279,200
Listing At
NSE
Sale Type
fresh issue
Fresh Issue
5,940,000 shares
(aggregating up to ₹204 Cr)
Offer for Sale
[.]
Reserved for Market Maker
313,200 shares
(aggregating up to ₹10.00 Cr)
Issue Type
book building
Open Date
21 May
Close Date
25 May
Allotment
26 May
Listing
29 May
Last updated: 4 months ago
| Date | IPO Issue Price (₹) | GMP (₹) | Est. Listing Price (₹) | Est. Profit Amount (₹) | Est. Profit % | Last Updated |
|---|---|---|---|---|---|---|
| 28 May 2026 Latest | ₹349 | ₹124 | ₹473 | ₹124 |
35.53%
|
10:36 AM |
| 27 May 2026 | ₹349 | ₹124 | ₹473 | ₹124 |
35.53%
|
5:20 PM |
Showing the 2 most recent GMP entries.
View full GMP historyLatest snapshot: 25 May 2026
| Category | Subscribed (x) | No. of Applications |
|---|---|---|
| QIB | 123.94x | 197 |
| NII | 146.33x | 49,781 |
| bNII (bids above ₹10L) | 178.82x | 31,162 |
| sNII (bids below ₹10L) | 81.35x | 18,619 |
| Individual Investors | 71.44x | 185,677 |
| Total | 102.49x | 285,436 |
Showing the latest subscription snapshot.
View full subscription historyThe promoters of the company are Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal.
New to lot sizes and investment limits? Read our guide on IPO lot size and minimum investment.
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 2 | 800 | ₹279,200 |
| Retail (Max) | 2 | 800 | ₹279,200 |
| S-HNI (Min) | 3 | 1,200 | ₹418,800 |
| S-HNI (Max) | 7 | 2,800 | ₹977,200 |
| B-HNI (Min) | 8 | 3,200 | ₹1,116,800 |
Want to understand how IPO shares are divided between investor categories? Read our guide on IPO reservation structure.
| Category | Shares Offered |
|---|---|
| QIB Shares Offered | 2,969,200 (47.48%) |
|
•
Anchor Investor Shares Offered
|
1,781,200 (28.48%) |
|
•
QIB (Ex. Anchor) Shares Offered
|
1,188,000 (19.00%) |
| NII (HNI) Shares Offered | 891,600 (14.26%) |
| Individual Investors Shares Offered | 2,079,200 (33.25%) |
| Market Maker Shares Offered | 313,200 (5.01%) |
| Total Shares Offered | 6,253,200 (100.00%) |
Q-Line Biotech has been quietly building its business since 2010, out of Lucknow, Uttar Pradesh. The company makes and sells diagnostic products — reagents, point-of-care test kits, consumables, and diagnostic equipment. Think of it as a B2B healthcare supplier that sits behind the scenes of pathology labs and clinics across India.
Financially, it's a mixed bag. Revenue is in the ₹100–500 crore range, and FY2025 showed a 56% jump in revenue — which sounds great. But profit after tax dropped 18% in the same year. So the top line is moving, but margins are clearly under pressure. Something worth watching before putting money in.
The company has GST registrations across 4 states and around 313 permanent employees on its rolls as of March 2025.
Standalone · ₹ in Crores
| Particulars | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Total Revenue | 184.81 | 206.45 | 322.58 |
| Profit After Tax (PAT) | 32.1 | 34.44 | 28.13 |
| EBITDA | 32.98 | 37.63 | 71.32 |
| Total Assets | 251.58 | 339.25 | 455.49 |
| Net Worth | 127.37 | 161.81 | 189.95 |
| Reserves & Surplus | 125.79 | 160.24 | 188.37 |
| Total Borrowing | 73.65 | 96.91 | 164.95 |
Revenue & Profit Trend
The basis of allotment for Q-Line Biotech IPO was finalised on 26 May 2026. You can check your allotment status using your PAN number or application number on the Purva Sharegistry (India) Private Limited portal or BSE.
The Q-Line Biotech IPO is expected to open in May 2026, subject to SEBI approval. Final dates will be updated once announced officially.
The price band for Q-Line Biotech IPO is ₹326.00 - ₹349.00 per share.
As per market sources, Q-Line Biotech IPO GMP is currently ₹124.00. GMP is tracked daily in the grey market. GMP indicates unofficial demand but does not guarantee listing gains.
The subscription status for Q-Line Biotech IPO stands at 102.49x overall.
The listing date for Q-Line Biotech IPO is 29 May 2026.
No comments yet. Be the first to comment!
